Scalper1 News
Regeneron Pharmaceuticals (REGN) says phase two-B testing for its dupilumab atopic dermatitis drug has been a success, setting up the drug for phase three testing this year. “While tonight’s news is clearly positive, we think it is more or less in line with investors’ expectations,” wrote Cowen analyst Phil Nadeau in a late Wednesday research note. Nadeau rates Regeneron stock as market perform, or hold. The drug is expected to treat moderate to Scalper1 News
Scalper1 News